-Cigna Rebates-Free Move Shakes PBM Industry, Stock Slammed
- The health insurer's shares fell sharply Thursday as executives detailed the financial impact of eliminating pharmacy benefit rebates, a move intended to lower drug costs for consumers.
- Cigna's stock price experienced a important decline on thursday, dropping over 15% by midmorning.
- The move aligns Cigna with growing pressure to increase openness in drug pricing and lower costs for consumers.
“`html
Cigna Stock Plummets After Announcing End too Pharmacy Rebates
Table of Contents
The health insurer’s shares fell sharply Thursday as executives detailed the financial impact of eliminating pharmacy benefit rebates, a move intended to lower drug costs for consumers.
What Happened?
Cigna’s stock price experienced a important decline on thursday, dropping over 15% by midmorning. this plunge followed the company’s proclamation that its pharmacy benefit manager, Express Scripts, will move to a rebate-free model for many commercial health plans starting in 2027.The decision, revealed earlier this week, aims to reduce medication costs but will initially impact Cigna’s profitability.
Why Eliminate Pharmacy rebates?
The move aligns Cigna with growing pressure to increase openness in drug pricing and lower costs for consumers. The Trump governance previously encouraged Pharmacy Benefit Managers (PBMs) to voluntarily eliminate rebates. Rebates, while lowering overall plan costs, often don’t translate directly into lower prices at the pharmacy counter for patients.
The Financial Impact
While CEO David Cordani initially highlighted the potential for 30% average cost reductions on branded drugs, Chief Operating Officer Steve Miller delivered the sobering financial news during the third-quarter earnings call. Eliminating rebates requires significant upfront investment, impacting the company’s projected profits in the coming years. The market reacted negatively to this disclosure, driving down Cigna’s stock price.
The shift to a rebate-free model fundamentally changes how PBMs generate revenue. Traditionally, PBMs negotiate rebates from drug manufacturers in exchange for favorable placement on formularies (lists of covered drugs). These rebates are a significant source of income for PBMs. Without them, PBMs will need to rely more on negotiating lower net prices directly with manufacturers and on administrative fees.
What Does This Mean for Consumers?
Theoretically, eliminating rebates should lead to lower out-of-pocket costs for consumers, notably for branded drugs. Though, the actual impact will depend on how effectively Cigna negotiates lower net prices with drug manufacturers. It’s also significant to note that the change won’t affect all plans; it applies primarily to commercial health plans starting in 2027.
Potential Benefits:
- Lower co-pays and coinsurance for branded medications.
- Increased transparency in drug pricing.
- Greater predictability in medication costs.
Potential Challenges:
- Drug manufacturers may not fully pass on the rebate savings to consumers.
- The impact on generic drug prices is less clear.
- Implementation complexities could delay or diminish the benefits.
Industry Context and Analysis
The PBM landscape is under increasing scrutiny. Federal regulators are